一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括Teclistamab；Lenalidomide，当前状态为招募中。登记地点显示中国北京、长春、河南省、山东省等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Teclistamab；Lenalidomide · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Chaoyang Hospital · 北京
- Peking University First Hospital · 北京
- The First Hospital of Jilin University · 长春
- Henan Cancer Hospital · 河南省
- Shandong Qilu Hospital · 山东省
- Shanghai Fourth People's Hospital · 上海
- Shengjing Hospital of China Medical University · 沈阳
- North China University of Science and Technology Affiliated Hospital.Hematology Department · 唐山
- Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science · 天津
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Tongji Hospital, Tongji Medical College of Hust · 武汉
- The First Affiliated Hospital, Zhejiang University College of Medicine · 浙江省
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.
- * Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.
- * Must not be intolerant to the starting dose of lenalidomide.
- * Must not have received any maintenance therapy.
- * Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
- * Have clinical laboratory values within prespecified range.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05243797；登记信息更新于 2026-10-07；本站同步于 2026-10-08，中国中心当前名额未经人工确认。